GlassScriptPhysician profile
David A Layne
NPI 1720045958
$6,356.84
in general payments reported to CMS, 2019-2025
37 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $718 · 2021: $1,514 · 2022: $1,110 · 2023: $1,231 · 2024: $476 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,075.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $803.10 | 2019-2025 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $770.47 | 2019-2023 | Xarelto |
| Amgen INC. | $663.21 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $565.50 | 2019-2025 | |
| Abbvie INC. | $509.18 | 2021-2025 | |
| Lilly USA, LLC | $471.67 | 2019-2023 | Mounjaro |
| Novo Nordisk INC | $272.83 | 2019-2025 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $179.90 | 2021-2023 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $173.33 | 2019-2021 | |
| Allergan, INC. | $170.12 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $167.50 | 2022-2024 | Quviviq |
| Eisai INC. | $148.52 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $135.35 | 2022-2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $126.04 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.21 | 2020-2024 | Xifaxan, Trulance |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Layne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.